STOCK TITAN

Freeline to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

LONDON, March 2, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics (Nasdaq: FRLN) announced that CEO Theresa Heggie will present at two virtual investor conferences in March. The presentations will take place at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, and the Barclays Global Healthcare Conference on March 10, 2021. Both presentations will be available on-demand on the Freeline website. The company, focused on gene therapies for inherited systemic diseases, has ongoing clinical programs for Hemophilia B and Fabry disease.

Positive
  • None.
Negative
  • None.

LONDON, March 02, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced today that Theresa Heggie, Chief Executive Officer, will present a company overview at the following virtual investor conferences in March:

  • H.C. Wainwright Global Life Sciences Conference on March 9, 2021, available on-demand beginning at 7.00 a.m. ET
  • Barclays Global Healthcare Conference on March 10, 2021, at 7:30 a.m. ET

The Company presentations from both conferences will be available on the investor relations section of the Freeline website at Freeline.life. Senior management will also participate in virtual one-on-one meetings with investors at these conferences.

About Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated systemic gene therapies. The Company is dedicated to improving patient lives through innovative, one-time treatments that provide functional cures for inherited systemic debilitating diseases. We use our proprietary, rationally-designed AAV vector, along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing protein into the patient’s bloodstream. Freeline’s integrated gene therapy platform includes in-house capabilities in research, clinical development, manufacturing and commercialization. The Company has clinical programs in Hemophilia B and Fabry disease, as well as preclinical programs in Gaucher disease and Hemophilia A. Freeline is headquartered in the UK and has operations in Germany and the US.

Contacts

David S. Arrington
Vice President Investor Relations & Corporate Communications
Freeline Therapeutics
david.arrington@freeline.life
+1 (646) 668 6947

Julia Wilson
JW Communications
juliawilsonuk@gmail.com
+44 (0) 7818 430877


FAQ

When will Freeline Therapeutics present at the H.C. Wainwright Global Life Sciences Conference?

Freeline Therapeutics will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021.

What is the focus of Freeline Therapeutics?

Freeline Therapeutics focuses on developing transformative gene therapies for inherited systemic debilitating diseases.

What are the scheduled dates for Freeline's investor presentations in March 2021?

Freeline's investor presentations are scheduled for March 9 and March 10, 2021.

Where can I find Freeline Therapeutics' conference presentations?

The presentations will be available on the investor relations section of Freeline's website.

What clinical programs is Freeline Therapeutics currently developing?

Freeline is developing clinical programs in Hemophilia B and Fabry disease.

Freeline Therapeutics Holdings plc

NASDAQ:FRLN

FRLN Rankings

FRLN Latest News

FRLN Stock Data

28.24M
26.80M
1.1%
45.88%
0.55%
Biotechnology
Healthcare
Link
United Kingdom
Stevenage